



Universitätsklinikum
Hamburg-Eppendorf

III. Medizinische Klinik
und Poliklinik
Direktor: Prof. Dr. T. Huber

Sektion Endokrinologie und
Diabetologie
Leiter: Prof. Dr. Jens Aberle

Zentrum für Innere Medizin
Martinistraße 52
20246 Hamburg
Telefon: (040) 7410-54412
Telefax: (040) 7410-45199

Universitätsklinikum Hamburg-Eppendorf Martinistraße 52 20246 Hamburg
III. Medizinische Klinik und Poliklinik

April 18, 2021

**Study Title: Pretreatment of patients expecting bariatric surgery with LGL-1 analog
Liraglutide**

EudraCT-Nr: 2011-003614-17

Phase IV Clinical Study

The initial intention of the trial was to investigate, if patients experience less nausea and vomiting after bariatric surgery following pharmacologic adaptation to higher GLP-1 levels (liraglutide). Inclusion criteria were adjusted to indication requirements for bariatric surgery at the time (2011) and label specific indications for treatment with liraglutide (type 2 diabetes mellitus). Liraglutide was approved by EMA for type 2 diabetes in 2009.

After completions of regulatory processes we experienced that by the time the study commenced the vast majority of type 2 diabetes patients referred for bariatric surgery were already on treatment with GLP-1 receptors agonists. Recruitment was therefore much more difficult than expected. With respect to the timeline a continuation of the study seemed unrealistic and we therefore decided to abort the clinical testing in a very early stage.

Sincerely,


Prof. Dr. med. J. Aberle

Universitätsklinikum Hamburg-Eppendorf
Körperschaft des öffentlichen Rechts
Gerichtsstand: Hamburg
UST-ID-Nr.: DE21 8618 948

Vorstandsmitglieder:
Prof. Dr. Burkhard Göke (Vorsitzender)
Prof. Dr. Blanche Schwappach-Pignataro
Joachim Prölß
Marya Verdel

Bankverbindung:
HSH Nordbank
Kto.-Nr.: 104364000; BLZ: 21050000
IBAN-Nr.: DE97210500000104364000
BIC: HSHNDEHH